Haematologica, Vol 94, Issue 10, 1453-1455 doi:10.3324/haematol.2009.008508
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Czibere, A.
Right arrow Articles by Germing, U.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Czibere, A.
Right arrow Articles by Germing, U.
Related Collections
Right arrowRelated Article

Myelodysplastic Syndromes

Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival

Akos Czibere, Ingmar Bruns, Bärbel Junge, Raminder Singh, Guido Kobbe, Rainer Haas, Ulrich Germing

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany

Correspondence: Akos Czibere, MD, Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf Moorenstraße 5, 40225 Duesseldorf, Germany. E-Mail address:Akos.Czibere{at}med.uni-duesseldorf.de

To further clarify the role of ribosomal protein S14 (RPS14) in myelodysplastic syndrome, we examined RPS14 transcription in bone marrow derived CD34+ cells from patients with non-5q- myelodysplastic syndrome and found a reduced expression of RPS14 in 51 of 72 (71%) patients. MDS patients with an intermediate-1 risk (INT-1) score according to the international prognostic scoring system and low RPS14 expression had a superior median overall survival of not reached versus 25 months compared to INT-1 patients with high RPS14 expression (p=0.0249). Using multivariate analysis, the RPS14 expression status was confirmed as an independent predictor for survival in INT-1 patients.

Key words: low RPS14, myelodysplastic syndromes, prolonged survival, 5q- aberration.


Related Article

Defective ribosome biogenesis in myelodysplastic syndromes
Naomi Galili, Samir Ahmed Qasim, Azra Raza
Haematologica 2009 94: 1336-1338. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 haematolHome page
N. Galili, S. A. Qasim, and A. Raza
Defective ribosome biogenesis in myelodysplastic syndromes
Haematologica, October 1, 2009; 94(10): 1336 - 1338.
[Full Text] [PDF]